ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 85 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q1 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $508,000 | -33.8% | 135,546 | -8.6% | 0.00% | -33.3% |
| Q3 2021 | $767,000 | +75.1% | 148,305 | +44.2% | 0.00% | +50.0% |
| Q2 2021 | $438,000 | -39.0% | 102,868 | -23.9% | 0.00% | -33.3% |
| Q1 2021 | $718,000 | +28.7% | 135,212 | +30.7% | 0.00% | +50.0% |
| Q4 2020 | $558,000 | -5.1% | 103,472 | +40.5% | 0.00% | 0.0% |
| Q3 2020 | $588,000 | +58.1% | 73,653 | +98.2% | 0.00% | 0.0% |
| Q2 2020 | $372,000 | +304.3% | 37,155 | +9.9% | 0.00% | +100.0% |
| Q1 2020 | $92,000 | -92.9% | 33,822 | -96.9% | 0.00% | -75.0% |
| Q4 2019 | $1,302,000 | -57.9% | 1,084,803 | -47.1% | 0.00% | -63.6% |
| Q3 2019 | $3,095,000 | -58.1% | 2,049,668 | +11.4% | 0.01% | -59.3% |
| Q2 2019 | $7,394,000 | +28.5% | 1,839,225 | +37.4% | 0.03% | +22.7% |
| Q1 2019 | $5,756,000 | -4.1% | 1,338,630 | +28.2% | 0.02% | -18.5% |
| Q4 2018 | $6,003,000 | +11.0% | 1,044,011 | +161.7% | 0.03% | +35.0% |
| Q3 2018 | $5,409,000 | – | 398,902 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |